MMP12 is a Potential Predictive and Prognostic Biomarker of Various Cancers Including Lung Adenocarcinoma.

OBJECTIVE

This study sought to explore the clinical value of matrix metalloproteinases 12 () in multiple cancers, including lung adenocarcinoma (LUAD).

METHODS

Using >10,000 samples, this retrospective study demonstrated the first pan-cancer analysis of . The expression of between cancer groups and their control groups was analyzed using Wilcoxon rank-sum tests. The clinical significance of expression in multiple cancers was assessed using receiver operating characteristic curves, Kaplan-Meier curves, and univariate Cox analysis. A further LUAD-related analysis based on 4565 multi-center and in-house samples was performed to verify the findings regarding MMP12 in pan-cancer analysis partly.

RESULTS

mRNA is highly expressed in 13 cancers compared to their controls, and the MMP12 protein level is elevated in some of these cancers (e.g., colon adenocarcinoma) ( < .05). expression makes it feasible to distinguish 21 cancer tissues from normal tissues (AUC = 0.86). A high expression is a prognosis risk factor in eight cancers, such as adrenocortical carcinoma (hazard ratio >1, < .05). The elevated expression is also a prognosis protective factor in breast-invasive carcinoma and colon adenocarcinoma (hazard ratio <1, < .05). Some pan-cancer findings regarding are verified in LUAD-MMP12 expression is upregulated in LUAD at both the mRNA and protein levels ( < .05), has the potential to distinguish LUAD with considerable accuracy (AUC = .91), and plays a risk prognosis factor for patients with the disease ( < .05).

CONCLUSIONS

is highly expressed in most cancers and may serve as a novel biomarker for the prediction and prognosis of numerous cancers.